1. Outcomes of coronary artery bypass grafting in patients with inflammatory rheumatic diseases: An 11-year nationwide cohort study 
Chao-Han Lai, MD, PhD, Wu-Wei Lai, MD, Meng-Jiun Chiou, BS, Liang-Miin Tsai, MD, Jih-Sheng Wen, MD, Chung-Yi Li, PhD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 149, Issue 3, Pages e2 (March 2015)
DOI: /j.jtcvs
Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
Study flow chart: cohort assembly of 40,639 adult patients undergoing first-time surgical revascularization for CAD between 2000 and 2010 in the NHIRD of Taiwan. ASp, Ankylosing spondylitis; CABG, coronary artery bypass grafting; IBD, inflammatory bowel disease; PM-DM, polymyositis-dermatomyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions

3. Figure 2
Kaplan–Meier estim ates of overall survival (A), freedom from myocardial infarction (B), and freedom from repeat revascularization (C) in patients without CAD-associated inflammatory rheumatic diseases (control group) and patients with RA, SLE, and ASp in the CABG cohort of Taiwan, The proportions and 95% CIs of overall survival, freedom from myocardial infarction, and freedom from repeat revascularization at 2, 4, 6, 8, and 10 years are summarized in Table E2. ASp, Ankylosing spondylitis; CABG, coronary artery bypass grafting; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2015 The American Association for Thoracic Surgery Terms and Conditions